Boosting Confidence in Early-Stage Drug Candidates Through Orthogonal Readouts & SAR Analysis
Time: 2:45 pm
Details:
• Integrating multiple assay platforms to validate hit specificity for targeting DHX9 and
KIF18A
• Adopting a SAR analysis approach for fine-turning compound structure and improving
bioactivity
• Combining assay expertise with deep cancer biology to succeed in hit binding and
minimize off-target effects
